UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 376

Sortiert nach

The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases

International journal of molecular sciences, 2021-10, Vol.22 (19), p.10773

2021

Volltextzugriff (PDF)

HBK-15, a Multimodal Compound, Showed an Anxiolytic-Like Effect in Rats

Neurochemical research, 2023-03, Vol.48 (3), p.839-845

2023

Volltextzugriff (PDF)

Effects of Acute Consumption of Noni and Chokeberry Juices vs. Energy Drinks on Blood Pressure, Heart Rate, and Blood Glucose in Young Adults

Evidence-based complementary and alternative medicine, 2019-08, Vol.2019, p.1-9

2019

Volltextzugriff (PDF)

Proces Boloński i powstanie Europejskiego Obszaru Szkolnictwa Wyższego

Rocznik integracji Europejskiej, 2017-12 (7), p.379

WESOŁOWSKA, ANNA

2017

Volltextzugriff (PDF)

Discovery of Novel pERK1/2- or β‑Arrestin-Preferring 5‑HT1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Journal of medicinal chemistry, 2020-10, Vol.63 (19), p.10946-10971

2020

Volltextzugriff (PDF)

Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo

Molecules (Basel, Switzerland), 2018-10, Vol.23 (10), p.2529

2018

Volltextzugriff (PDF)

The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and β-arrestin signalling

Journal of psychopharmacology (Oxford), 2020-12, Vol.34 (12), p.1431-1442

2020

Volltextzugriff (PDF)

Selective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats

Pharmaceuticals (Basel, Switzerland), 2023-01, Vol.16 (2), p.154

2023

Volltextzugriff (PDF)

Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia

European journal of medicinal chemistry, 2022-04, Vol.233, p.114218-114218, Article 114218

2022

Volltextzugriff (PDF)

Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice

European journal of pharmacology, 2007-01, Vol.555 (1), p.43-47

2007

Volltextzugriff (PDF)

Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity

Journal of medicinal chemistry, 2019-03, Vol.62 (5), p.2750-2771

2019

Volltextzugriff (PDF)

The selective 5-HT6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats

European journal of pharmacology, 2008-03, Vol.582 (1-3), p.88-93

2008

Volltextzugriff (PDF)

Novel Arylsulfonamide Derivatives with 5‑HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia

Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4543-4557

2014

Volltextzugriff (PDF)

Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo

European journal of medicinal chemistry, 2020-10, Vol.203, p.112529, Article 112529

2020

Volltextzugriff (PDF)

Study into a possible mechanism responsible for the antidepressant-like activity of the selective 5-HT6 receptor antagonist SB-399885 in rats

Pharmacological reports, 2007-11, Vol.59 (6), p.664-671

Wesołowska, Anna

2007

Volltextzugriff (PDF)

First-in-Class Selenium-Containing Potent Serotonin Receptor 5‑HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease

Journal of medicinal chemistry, 2024-01, Vol.67 (2), p.1580-1610

2024

Volltextzugriff (PDF)

Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro

Molecules (Basel, Switzerland), 2019-12, Vol.24 (24), p.4472

2019

Volltextzugriff (PDF)

Novel 3‑(1,2,3,6-Tetrahydropyridin-4-yl)‑1H‑indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity

Journal of medicinal chemistry, 2017-09, Vol.60 (17), p.7483-7501

2017

Volltextzugriff (PDF)

Potential antidepressant and anxiolytic properties of new phenylpiperazine derivaties

Pharmacological reports, 2012-03, Vol.64 (2), p.503-503

2012

Volltextzugriff (PDF)

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

Journal of medicinal chemistry, 2021-09, Vol.64 (17), p.12603-12629

2021

Volltextzugriff (PDF)

Possibilities of delaying skin aging processes with the use of selectedmedicinal substances

Farmacja Polska, 2019-07, Vol.75 (7), p.369-376

2019

Volltextzugriff (PDF)

The preclinical discovery and development of cariprazine for the treatment of schizophrenia

Expert opinion on drug discovery, 2018-08, Vol.13 (8), p.779-790

2018

Volltextzugriff (PDF)

Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease

European journal of medicinal chemistry, 2023-11, Vol.259, p.115695-115695, Article 115695

2023

Volltextzugriff (PDF)

Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents

European journal of medicinal chemistry, 2023-11, Vol.260, p.115756, Article 115756

2023

Volltextzugriff (PDF)

Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability

Bioorganic & medicinal chemistry, 2019-09, Vol.27 (18), p.4163-4173

2019

Volltextzugriff (PDF)

26 – 50 von 376

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(353)
Mit Volltextzugriff
(343)

Publikationsform

Sprache

Englisch
(356)
Polnisch
(30)
Japanisch
(13)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(210)
Life Sciences & Biomedicine
(190)
Pharmacology & Pharmacy
(109)
Animals
(104)
Humans
(86)
Male
(85)
Rats
(56)
Chemistry, Medicinal
(52)
5-Ht
(45)
Mice
(44)
Physical Sciences
(40)
Structure-Activity Relationship
(40)
Receptors, Serotonin - Metabolism
(37)
Biochemistry & Molecular Biology
(35)
Chemistry
(35)
Antidepressive Agents - Pharmacology
(33)
Female
(32)
Dose-Response Relationship, Drug
(31)
Rats, Wistar
(31)
Biological And Medical Sciences
(28)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases

HBK-15, a Multimodal Compound, Showed an Anxiolytic-Like Effect in Rats

Effects of Acute Consumption of Noni and Chokeberry Juices vs. Energy Drinks on Blood Pressure, Heart Rate, and Blood Glucose in Young Adults

Proces Boloński i powstanie Europejskiego Obszaru Szkolnictwa Wyższego

Discovery of Novel pERK1/2- or β‑Arrestin-Preferring 5‑HT1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo

The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and β-arrestin signalling

Selective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats

Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia

Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice

Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity

The selective 5-HT6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats

Novel Arylsulfonamide Derivatives with 5‑HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia

Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo

Study into a possible mechanism responsible for the antidepressant-like activity of the selective 5-HT6 receptor antagonist SB-399885 in rats

First-in-Class Selenium-Containing Potent Serotonin Receptor 5‑HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease

Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro

Novel 3‑(1,2,3,6-Tetrahydropyridin-4-yl)‑1H‑indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity

Potential antidepressant and anxiolytic properties of new phenylpiperazine derivaties

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

Possibilities of delaying skin aging processes with the use of selectedmedicinal substances

The preclinical discovery and development of cariprazine for the treatment of schizophrenia

Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease

Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents

Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability

Suchergebnisse filtern